Exagen Inc

Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. It operates under the Avise brand. The company was founded by Waneta C. Tuttle and Cole Harris in 2002 and is headquartered in Vista, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Exagen Inc reports robust Q1 revenue growth and strategic expansion

Exagen Inc's Q1 performance reflects strong revenue growth and improved financial outlook, driven by enhanced ASP and strategic initiatives.
Despite challenges in initial demand impact and regulatory monitoring, the company remains optimistic about future growth prospects and market positioning.
With a focus on innovation, market expansion, and operational efficiency, Exagen Inc aims to capitalize on opportunities for sustained growth and competitive advantage.

Exagen Inc reports strong Q2 performance, eyes growth through innovation

Exagen Inc's Q2 performance reflects significant improvement in financial metrics, revenue growth, and progress towards profitability, driven by increased clinical adoption and strategic initiatives.
The company's focus on innovation, market expansion, and customer engagement through new markers, biopharma contracts, and educational campaigns positions them for sustained growth and competitive advantage.
While challenges persist in achieving profitability and market acceptance, Exagen's proactive approach to addressing these hurdles and leveraging opportunities bodes well for their future success and market leadership.

Exagen Inc reports progress in revenue growth and innovation initiatives

Exagen Inc's Q3 2024 earnings call highlighted both achievements and challenges, with a focus on revenue growth, innovation, and operational improvements. The company is poised for growth with upcoming product launches and a strategic approach to enhancing the clinician experience. Challenges remain in achieving profitability and managing capacity expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The suite of innovative biomarker assays seeks to further aid clinicians in the diagnosis, prognosis and monitoring of patients with autoimmune diseases The suite of innovative biomarker assays seeks to further aid clinicians in the diagnosis, prognosis and monitoring of patients with autoimmune diseases

Exagen Inc., Allegheny Health Network Research Institute and AHN Autoimmunity Institute Announce Collaboration to Develop Novel Patented Biomarkers into Clinical Diagnostic Tests

Exagen Inc. (XGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Exagen Inc. (XGN) Q1 Earnings Expected to Decline

SAN DIEGO, May 03, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of awareness initiatives and educational tools highlighting the importance of an accurate and timely diagnosis and patient monitoring for Systemic Lupus Erythematosus (SLE).

Exagen Announces New Campaign and Initiatives for Lupus Awareness Month

SAN DIEGO, April 27, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2021 after the market close on Tuesday, May 11, 2021. Ron Rocca, Exagen's President and Chief Executive Officer, Kamal Adawi, Chief Financial Officer, and Mark Hazeltine, Chief Operating Officer, will host a conference call to review the Company's results at 4:30 PM Eastern Time (1:30 PM Pacific Time).

Exagen to Announce First Quarter 2021 Financial Results on May 11, 2021

SAN DIEGO, March 29, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that it will collaborate with Emory University on a new study about the long-term effects of COVID-19 infection in the development of autoimmune diseases. Emory is widely acknowledged as a leading research institution in the study of various autoimmune diseases, including lupus.

Exagen Inc. Announces Study on the Long-Term Effects of COVID-19 Infection in the Development of Autoimmune Diseases

SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has closed its previously announced underwritten public offering of 4,255,000 shares of its common stock, including 555,000 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares, at a price to the public of $16.25 per share. The gross proceeds to Exagen from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were approximately $69.1 million.

Exagen Inc. Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

SAN DIEGO, March 22, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of an underwritten public offering of 3,700,000 shares of its common stock at a price to the public of $16.25 per share. All of the shares to be sold in the offering are to be sold by Exagen. The gross proceeds to Exagen from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $60.1 million. In addition, Exagen has granted the underwriters a 30-day option to purchase up to an additional 555,000 shares of common stock. The offering is expected to close on or about March 25, 2021, subject to the satisfaction of customary closing conditions.

Exagen Inc. Announces Pricing of Public Offering of Common Stock

SAN DIEGO, March 22, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. In addition, Exagen intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares to be sold in the offering are to be sold by Exagen. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Exagen Inc. Announces Proposed Public Offering of Common Stock

Exagen Inc. (XGN) CEO Ron Rocca on Q4 2020 Results - Earnings Call Transcript

Quarterly Records: Revenue, Gross Margin, AVISE® CTD Volumes and Adopters Quarterly Records: Revenue, Gross Margin, AVISE® CTD Volumes and Adopters

Exagen Inc. Reports Fourth Quarter and Full Year 2020 Results

Exagen (XGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Exagen (XGN)

Exagen Inc. (XGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Exagen Inc. (XGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Exagen Inc. (XGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Exagen Inc. (XGN) Stock Jumps 6.8%: Will It Continue to Soar?

SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading autoimmune organization, will release financial results for the quarter and year ended December 31, 2020 after the market close on Tuesday, March 16, 2021. Ron Rocca, President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company's results at 4:30 PM Eastern Time (1:30 PM Pacific Time).

Exagen to Announce Fourth Quarter and Full Year Financial Results on March 16, 2021

SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading autoimmune organization, today announced its participation in the Cowen 41st Annual Health Care Conference which takes place March 1-4, 2021. Ron Rocca, Exagen's President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will participate in a virtual fireside chat on Wednesday, March 3 at 4:00 pm EST.

Exagen Inc. to Participate in the Cowen 41st Annual Health Care Conference

SAN DIEGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading autoimmune organization, today announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 17-19, 2021. Ron Rocca, Exagen's President and Chief Executive Officer, and Kamal Adawi, Exagen's Chief Financial Officer, will participate in a virtual fireside chat on Wednesday, February 17 at 3:00 PM ET, which is accessible to conference attendees. Management will also be participating in one-on-one meetings with investors during the event; meetings can be requested through BTIG.

Exagen Inc. To Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

SAN DIEGO, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that all AVISE test offerings (CTD, Lupus, SLE Prognostic, SLE Monitor, APS, Vasculitis AAV, MTX, and HCQ) are now a contracted in-network service with Tufts Medical Center, an internationally-respected academic medical center.

Exagen Inc. Partners with Boston's Tufts Medical Center to Offer AVISE® Testing as an In-Network Benefit for Patients Suffering from Debilitating Autoimmune Diseases

Record Testing Revenue, Adopters and AVISE CTD® Volumes

Exagen Inc. Reports Preliminary Fourth Quarter 2020 Testing Results

SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that company management will participate in the 2021 ICR Conference, which takes place January 11-14, 2021. Ron Rocca, Exagen's President and Chief Executive Officer, and Kamal Adawi, Exagen's Chief Financial Officer, will participate in a virtual fireside chat on Thursday, January 14 at 11:30 AM ET, which is accessible to conference attendees. Management will also be participating in one-on-one meetings with investors during the event; meetings can be requested through the ICR Conference site.

Exagen Inc. To Participate in 2021 ICR Conference

SAN DIEGO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that all AVISE test offerings (CTD, Lupus, SLE Prognostic, SLE Monitor, APS, Vasculitis AAV, MTX, and HCQ) are a contracted in-network service with St. Charles Health System, the largest provider of medical care in Central Oregon.

Exagen Inc. Partners with Oregon's St. Charles Health System to Offer AVISE® Testing as an In-Network Benefit for Patients Suffering from Debilitating Autoimmune Diseases

Exagen (XGN) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Exagen (XGN) Looks Good: Stock Adds 9.3% in Session

Transmedics Group Inc

Myomo

Three currently-undervalued MedTech stocks are flourishing on the back of a few uptrends.

3 Beaten-Down MedTech Stocks Set to Stage a Comeback in 2021

SAN DIEGO, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that company management will participate in the following December investor conferences:

Exagen Inc. to Participate in December Investor Conferences

SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that it has extended its collaboration agreement with GlaxoSmithKline plc (GSK), one of the world's leading healthcare companies, to raise awareness of the importance of timely diagnosis of systemic lupus erythematosus (SLE), the most common and severe form of lupus. At the center of the program are the proprietary AVISE® laboratory tests, which can facilitate early diagnosis and management of SLE, a complex, incurable autoimmune disease. The details of the agreement are confidential.

Exagen and GSK partner for 4th straight year, driving greater awareness of challenges facing lupus diagnosis and management

Exagen Inc. (XGN) CEO Ron Rocca on Q3 2020 Results - Earnings Call Transcript

News for Exagen Inc Stock (XGN)